tradingkey.logo

Guardant Health Inc

GH
63.380USD
+0.540+0.86%
Cierre 10/06, 16:00ETCotizaciones retrasadas 15 min
7.89BCap. mercado
PérdidaP/E TTM

Guardant Health Inc

63.380
+0.540+0.86%

Más Datos de Guardant Health Inc Compañía

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Información de Guardant Health Inc

Símbolo de cotizaciónGH
Nombre de la empresaGuardant Health Inc
Fecha de salida a bolsaOct 04, 2018
Director ejecutivoDr. Amirali Talasaz, Ph.D.
Número de empleados1999
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 04
Dirección3100 Hanover Street
CiudadPALO ALTO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94304
Teléfono18556988887
Sitio Webhttps://guardanthealth.com/
Símbolo de cotizaciónGH
Fecha de salida a bolsaOct 04, 2018
Director ejecutivoDr. Amirali Talasaz, Ph.D.

Ejecutivos de Guardant Health Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
2.52M
+0.47%
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.47M
+0.48%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
88.53K
+9.85%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.17K
+14.83%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
44.32K
+18.23%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
+37.83%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
21.68K
+31.56%
Ms. Myrtle Stephens Potter
Ms. Myrtle Stephens Potter
Independent Director
Independent Director
18.28K
+0.23%
Ms. Meghan V. Joyce
Ms. Meghan V. Joyce
Independent Director
Independent Director
11.18K
-0.89%
Mr. Musa Tariq
Mr. Musa Tariq
Independent Director
Independent Director
7.59K
+1.78%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
2.52M
+0.47%
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.47M
+0.48%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
88.53K
+9.85%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.17K
+14.83%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
44.32K
+18.23%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
+37.83%

Desglose de ingresos

Divisa: USDActualizado: hace 5 horas
Divisa: USDActualizado: hace 5 horas
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Oncology
158.69M
68.37%
Biopharma and data
56.02M
24.14%
Screening
14.81M
6.38%
Licensing and other
2.57M
1.11%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
216.68M
93.36%
International
15.40M
6.64%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Oncology
158.69M
68.37%
Biopharma and data
56.02M
24.14%
Screening
14.81M
6.38%
Licensing and other
2.57M
1.11%

Estadísticas de accionistas

Actualizado: dom., 28 de sep
Actualizado: dom., 28 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.74%
BlackRock Institutional Trust Company, N.A.
6.73%
Capital International Investors
3.99%
Baillie Gifford & Co.
3.86%
Deep Track Capital LP
3.41%
Otro
72.28%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.74%
BlackRock Institutional Trust Company, N.A.
6.73%
Capital International Investors
3.99%
Baillie Gifford & Co.
3.86%
Deep Track Capital LP
3.41%
Otro
72.28%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
45.84%
Investment Advisor/Hedge Fund
27.21%
Hedge Fund
19.41%
Individual Investor
4.36%
Bank and Trust
2.25%
Sovereign Wealth Fund
1.83%
Research Firm
1.74%
Pension Fund
1.17%
Family Office
0.03%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
750
124.14M
99.55%
-16.44M
2025Q2
759
134.16M
107.59%
-14.14M
2025Q1
783
130.34M
105.23%
-16.59M
2024Q4
746
130.16M
105.47%
-20.09M
2024Q3
780
137.29M
111.53%
-9.70M
2024Q2
801
127.50M
103.74%
-18.45M
2024Q1
826
124.00M
101.88%
-12.71M
2023Q4
856
120.18M
99.30%
-14.26M
2023Q3
867
117.78M
100.31%
-19.15M
2023Q2
890
119.83M
102.55%
+840.96K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
12.14M
9.74%
+89.50K
+0.74%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.39M
6.73%
-215.41K
-2.50%
Jun 30, 2025
Capital International Investors
4.98M
3.99%
-171.27K
-3.33%
Jun 30, 2025
Baillie Gifford & Co.
4.81M
3.86%
-251.22K
-4.96%
Jun 30, 2025
Deep Track Capital LP
4.25M
3.41%
-1.19M
-21.93%
Jun 30, 2025
Two Sigma Investments, LP
4.24M
3.4%
+42.75K
+1.02%
Jun 30, 2025
Eventide Asset Management, LLC
3.46M
2.77%
-107.78K
-3.02%
Jun 30, 2025
Invesco Advisers, Inc.
3.40M
2.73%
+789.69K
+30.20%
Jun 30, 2025
Cadian Capital Management LP
3.18M
2.55%
-1.42M
-30.81%
Jun 30, 2025
Citadel Advisors LLC
2.94M
2.36%
-658.36K
-18.30%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: hace 15 horas
Actualizado: hace 15 horas
Nombre
Proporción
Global X Genomics & Biotechnology ETF
5.38%
ARK Genomic Revolution ETF
5.3%
Franklin Genomic Advancements ETF
5.28%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.58%
Invesco Dorsey Wright Healthcare Momentum ETF
3.15%
SPDR S&P Health Care Services ETF
2.68%
Alger Mid Cap 40 ETF
2.55%
ROBO Global Healthcare Technology & Innovation ETF
2.47%
iShares Health Innovation Active ETF
1.92%
iShares U.S. Healthcare Providers ETF
1.37%
Ver más
Global X Genomics & Biotechnology ETF
Proporción5.38%
ARK Genomic Revolution ETF
Proporción5.3%
Franklin Genomic Advancements ETF
Proporción5.28%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción3.58%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción3.15%
SPDR S&P Health Care Services ETF
Proporción2.68%
Alger Mid Cap 40 ETF
Proporción2.55%
ROBO Global Healthcare Technology & Innovation ETF
Proporción2.47%
iShares Health Innovation Active ETF
Proporción1.92%
iShares U.S. Healthcare Providers ETF
Proporción1.37%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI